Matrix extracellular phosphoglycoprotein: Difference between revisions
No edit summary |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 6: | Line 6: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
==Further reading== | ==Further reading== | ||
| Line 23: | Line 23: | ||
{{refend}} | {{refend}} | ||
{{PBB_Controls | {{PBB_Controls | ||
| update_page = yes | | update_page = yes | ||
Latest revision as of 19:28, 4 September 2012
Matrix, extracellular phosphoglycoprotein with ASARM motif (bone), also known as MEPE, is a human gene.[1]
Phosphatonins have a role in phosphate homeostasis and the relationship between phosphate handling by the kidney and gastrointestinal tract. Matrix extracellular phosphoglycoprotein (MEPE), one of several candidate phosphatonins, promotes phosphaturia.[2] Short-term infusion of MEPE inhibits phosphate absorption in the jejunum but not the duodenum.[2] The phosphaturic action of MEPE may correlate with a significant reduction in renal sodium-phosphate co-transporter NaPi-IIa in the proximal convoluted tubules of the outer renal cortex.[2] This short-term inhibitory effect of MEPE on renal and intestinal phosphate handling occurs without changes in the circulating levels of parathyroid hormone (PTH), 1,25-dihydroxyvitamin D(3), or fibroblast growth factor 23 (FGF23).[2] MEPE may be involved in phosphate homeostasis, acting in both the kidney and the gastrointestinal tract.[2]
References
- ↑ "Entrez Gene: MEPE matrix, extracellular phosphoglycoprotein with ASARM motif (bone)".
- ↑ 2.0 2.1 2.2 2.3 2.4 Marks J, Churchill LJ, Debnam ES, Unwin RJ (2008). "Matrix extracellular phosphoglycoprotein inhibits phosphate transport". J Am Soc Nephrol. 19 (12): 2313–20. PMID 19005008. Unknown parameter
|month=ignored (help)
Further reading
- Quarles LD (2003). "FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization". Am. J. Physiol. Endocrinol. Metab. 285 (1): E1–9. doi:10.1152/ajpendo.00016.2003. PMID 12791601.
- Ogbureke KU, Fisher LW (2005). "Renal expression of SIBLING proteins and their partner matrix metalloproteinases (MMPs)". Kidney Int. 68 (1): 155–66. doi:10.1111/j.1523-1755.2005.00389.x. PMID 15954904.
- Ogbureke KU, Fisher LW (2004). "Expression of SIBLINGs and their partner MMPs in salivary glands". J. Dent. Res. 83 (9): 664–70. doi:10.1177/154405910408300902. PMID 15329369.
- Jain A, Fedarko NS, Collins MT; et al. (2004). "Serum levels of matrix extracellular phosphoglycoprotein (MEPE) in normal humans correlate with serum phosphorus, parathyroid hormone and bone mineral density". J. Clin. Endocrinol. Metab. 89 (8): 4158–61. doi:10.1210/jc.2003-032031. PMID 15292364.
- Nampei A, Hashimoto J, Hayashida K; et al. (2005). "Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone". J. Bone Miner. Metab. 22 (3): 176–84. doi:10.1007/s00774-003-0468-9. PMID 15108058.
- MacDougall M, Simmons D, Gu TT, Dong J (2003). "MEPE/OF45, a new dentin/bone matrix protein and candidate gene for dentin diseases mapping to chromosome 4q21". Connect. Tissue Res. 43 (2–3): 320–30. doi:10.1080/713713461. PMID 12489176.
- Argiro L, Desbarats M, Glorieux FH, Ecarot B (2001). "Mepe, the gene encoding a tumor-secreted protein in oncogenic hypophosphatemic osteomalacia, is expressed in bone". Genomics. 74 (3): 342–51. doi:10.1006/geno.2001.6553. PMID 11414762.
- Rowe PS, de Zoysa PA, Dong R; et al. (2000). "MEPE, a new gene expressed in bone marrow and tumors causing osteomalacia". Genomics. 67 (1): 54–68. doi:10.1006/geno.2000.6235. PMID 10945470.